Re-escalation of anti-TNF therapy is common among older adults with RA and typically occurs within 6 months of prior de-escalation.
The cytokine TNF signals via two distinct receptors, TNF receptor 1 (TNFR1) and TNFR2, and is a central mediator of various immune-mediated diseases. Indeed, TNF-neutralizing biologic drugs have been ...
Rheumatoid arthritis (RA) is a classic autoimmune disease with a decade-long preclinical phase during which patients lose self-tolerance and begin to produce autoantibodies against ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results